{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:47:00Z","timestamp":1791841620292,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.obpill.2026.100335","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:45:49Z","timestamp":1789832749000},"page":"100335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fat and lean mass changes during incretin-based therapy with structured exercise and nutritional support: A retrospective real-world pilot study"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-5661","authenticated-orcid":false,"given":"Meral","family":"Kucuk Yetgin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4400-4428","authenticated-orcid":false,"given":"Nana","family":"Gletsu-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7173-1976","authenticated-orcid":false,"given":"Robert F.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1223-3633","authenticated-orcid":false,"given":"Eitan","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1986-0833","authenticated-orcid":false,"given":"John","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7332-2260","authenticated-orcid":false,"given":"Donny","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1244-515X","authenticated-orcid":false,"given":"Dustin","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.obpill.2026.100335_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World health organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.obpill.2026.100335_bib2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","article-title":"The weight-loss effect of GLP-1 RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials","volume":"118","author":"Liu","year":"2023","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.obpill.2026.100335_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.obpill.2026.100335_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"10","key":"10.1016\/j.obpill.2026.100335_bib5","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.obpill.2026.100335_bib6","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"J Endocr Soc"},{"issue":"5","key":"10.1016\/j.obpill.2026.100335_bib7","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.obpill.2026.100335_bib8","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1111\/dom.70666","article-title":"Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials","volume":"28","author":"Eisa","year":"2026","journal-title":"Diabetes Obes Metabol"},{"issue":"18","key":"10.1016\/j.obpill.2026.100335_bib9","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.obpill.2026.100335_bib10","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s40279-025-02386-0","article-title":"Physical fitness with exercise and glucagon-like peptide-1 receptor agonist treatment alone or combined after diet-induced weight loss: a secondary analysis of a randomized controlled trial in adults with obesity","volume":"56","author":"Jensen","year":"2026","journal-title":"Sports Med"},{"key":"10.1016\/j.obpill.2026.100335_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2025.1720794","article-title":"GLP-1 agonists and exercise: the future of lifestyle prioritization","volume":"6","author":"Codella","year":"2025","journal-title":"Front Clin Diabetes Healthc"},{"issue":"4","key":"10.1016\/j.obpill.2026.100335_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/oby.70164","article-title":"Joint TOS\/OMA\/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach","volume":"34","author":"Alexander","year":"2026","journal-title":"Obesity"},{"issue":"8","key":"10.1016\/j.obpill.2026.100335_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1249\/JSR.0000000000001272","article-title":"The role of exercise in the contemporary era of obesity management medications","volume":"24","author":"Jakicic","year":"2025","journal-title":"Curr Sports Med Rep"},{"issue":"1","key":"10.1016\/j.obpill.2026.100335_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American college of lifestyle medicine, the American society for nutrition, the obesity medicine association, and the obesity society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.obpill.2026.100335_bib15","series-title":"ACSM's guidelines for exercise testing and prescription","year":"2026"},{"issue":"1","key":"10.1016\/j.obpill.2026.100335_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/doci25-0008","article-title":"Pharmacologic treatment of obesity in adults: standards of care in overweight and obesity","volume":"1","year":"2026","journal-title":"Diabetes, Obesity, and CardioMetabolic CARE"},{"issue":"1","key":"10.1016\/j.obpill.2026.100335_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes Rev"},{"issue":"9","key":"10.1016\/j.obpill.2026.100335_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/obr.70189","article-title":"Comparative efficacy of GLP-1 receptor agonists, exercise, and their combination on body composition and glucolipid metabolism in adults with overweight or obesity: a network meta-analysis of randomized controlled trials","volume":"27","author":"Vandoni","year":"2026","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.obpill.2026.100335_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.obpill.2026.100335_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.31128\/AJGP-09-24-7411","article-title":"Pharmacotherapy for the management of overweight and obesity","volume":"54","author":"Forner","year":"2025","journal-title":"Aust J Gen Pract"},{"issue":"6","key":"10.1016\/j.obpill.2026.100335_bib21","first-page":"675","article-title":"An experimental study of physical fitness of air force personnel","volume":"10","author":"Balke","year":"1959","journal-title":"U S Armed Forces Med J"},{"key":"10.1016\/j.obpill.2026.100335_bib22","series-title":"RStudio: integrated development environment for R [Internet]","year":"2025"},{"key":"10.1016\/j.obpill.2026.100335_bib23","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"issue":"3","key":"10.1016\/j.obpill.2026.100335_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF02289138","article-title":"Rank-biserial correlation","volume":"21","author":"Cureton","year":"1956","journal-title":"Psychometrika"},{"issue":"4","key":"10.1016\/j.obpill.2026.100335_bib25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/obr.12143","article-title":"Weight loss composition is one-fourth fat-free mass: a a critical review and critique of this widely cited rule","volume":"15","author":"Heymsfield","year":"2014","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.obpill.2026.100335_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13370","article-title":"The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis","volume":"23","author":"Nuijten","year":"2022","journal-title":"Obes Rev"},{"issue":"9","key":"10.1016\/j.obpill.2026.100335_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:09:06Z","timestamp":1791839346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":27,"alternative-id":["S2667368126000914"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100335","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fat and lean mass changes during incretin-based therapy with structured exercise and nutritional support: A retrospective real-world pilot study","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100335"}}